Optimization of the Solvent and In Vivo Administration Route of Auranofin in a Syngeneic Non-Small Cell Lung Cancer and Glioblastoma Mouse Model
Open Access
- 9 December 2022
- journal article
- research article
- Published by MDPI AG in Pharmaceutics
- Vol. 14 (12), 2761
- https://doi.org/10.3390/pharmaceutics14122761
Abstract
The antineoplastic activity of the thioredoxin reductase 1 (TrxR) inhibitor, auranofin (AF), has already been investigated in various cancer mouse models as a single drug, or in combination with other molecules. However, there are inconsistencies in the literature on the solvent, dose and administration route of AF treatment in vivo. Therefore, we investigated the solvent and administration route of AF in a syngeneic SB28 glioblastoma (GBM) C57BL/6J and a 344SQ non-small cell lung cancer 129S2/SvPasCrl (129) mouse model. Compared to daily intraperitoneal injections and subcutaneous delivery of AF via osmotic minipumps, oral gavage for 14 days was the most suitable administration route for high doses of AF (10–15 mg/kg) in both mouse models, showing no measurable weight loss or signs of toxicity. A solvent comprising 50% DMSO, 40% PEG300 and 10% ethanol improved the solubility of AF for oral administration in mice. In addition, we confirmed that AF was a potent TrxR inhibitor in SB28 GBM tumors at high doses. Taken together, our results and results in the literature indicate the therapeutic value of AF in several in vivo cancer models, and provide relevant information about AF’s optimal administration route and solvent in two syngeneic cancer mouse models.Funding Information
- Research Foundation Flanders (11E7719 N, 1520819 N)
- Olivia Fund (21OCL06)
This publication has 64 references indexed in Scilit:
- Susceptibility of Human Head and Neck Cancer Cells to Combined Inhibition of Glutathione and Thioredoxin MetabolismPLOS ONE, 2012
- Enhancement of Carboplatin-Mediated Lung Cancer Cell Killing by Simultaneous Disruption of Glutathione and Thioredoxin MetabolismClinical Cancer Research, 2011
- Coding of facial expressions of pain in the laboratory mouseNature Methods, 2010
- Cancer cell death induced by phosphine gold(I) compounds targeting thioredoxin reductaseBiochemical Pharmacology, 2010
- Cortical and Subcortical Contributions to Stop Signal Response Inhibition: Role of the Subthalamic NucleusJournal of Neuroscience, 2006
- PHARMACOLOGY AND DRUG THERAPYPublished by Elsevier BV ,2005
- AuranofinRheumatology, 1997
- A New Structural Transition of Serum Albumin Dependent on the State of Cys34JBIC Journal of Biological Inorganic Chemistry, 1994
- Cellular and molecular pharmacology of auranofin and related gold complexesBiochemical Pharmacology, 1986
- AuranofinDrugs, 1984